The landscape of drug development for ultra-rare diseases is undergoing a significant transformation, driven by the U.S. Food and Drug…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
In a landmark move poised to reshape the landscape of pharmaceutical innovation, Insilico Medicine, a pioneer in artificial intelligence (AI)-driven…
Read More
Fake testimonials, no pharmacy and an FDA warning: how Medvi built a $1.8 billion telehealth company in the gaps between regulators
The recent profile of Medvi by The New York Times earlier this month highlighted the company as a prime example…
Read More
Protecting Innovation in a Borderless Pharma Economy: The Reality of Globalized Pharma Innovation
The pharmaceutical industry, traditionally a bastion of national innovation, has evolved into a truly borderless enterprise. Today’s drug development programs…
Read More
Pharmaceutical Industry Navigates Sustainability Paradox as Emissions Continue to Climb
The global pharmaceutical and biotechnology sectors, integral components of the broader healthcare industry, are grappling with a significant environmental paradox:…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
Amazon Web Services (AWS) today unveiled Amazon Bio Discovery, a groundbreaking application designed to drastically accelerate the drug discovery process…
Read More
Immuto Scientific Pairs AI and Mass Spectrometry for a Step Change in Protein Structure Throughput
Immuto Scientific, a trailblazing company co-founded in 2018 by electrical engineers Faraz A. Choudhury, Ph.D. (CEO) and Daniel Benjamin, Ph.D.…
Read More
Lilly’s plans to buy CAR-T firm Kelonia in deal worth up to $7 billion. Can its deal spree avoid Pfizer’s fate?
Eli Lilly and Company, currently buoyed by the explosive success of its GLP-1 franchise, has announced its intent to acquire…
Read More
EClinical Solutions study models 241% ROI from AI-powered clinical trial data platform
The pharmaceutical industry, perpetually challenged by the immense costs, protracted timelines, and inherent complexities of bringing new therapies to market,…
Read More
Chinese firms landed 6 of 26 major pharma deals in 16 months, worth $53 billion
The majority of these high-value collaborations, roughly half, involved firms of U.S. origin, predominantly structured as mergers and acquisitions (M&A).…
Read MoreYOU MAY HAVE MISSED
